查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1715817

生物模擬市場：按產品、交付模式、應用和最終用戶分類－2025-2030 年全球預測

Biosimulation Market by Offering, Delivery Model, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年生物模擬市場價值將達31億美元，2024年將達35.5億美元，複合年成長率為14.60%，2030年將達80.7億美元。

主要市場統計數據
基準年2023年 31億美元
預計2024年 35.5億美元
預測年份 2030 80.7億美元
複合年成長率（%） 14.60%

生物模擬已成為重塑生命科學格局的重要工具。該領域將先進的計算演算法與生物數據相結合，以簡化和加強研究工作，為傳統實驗程序提供更準確、更具成本效益的替代方案。如今，創新公司正在轉向能夠預測治療結果、模擬藥物交互作用和最佳化臨床試驗設計的系統。透過利用先進的模擬工具，市場開發正在加快開發週期、改善決策並降低藥物發現和開發風險。隨著數位技術的廣泛使用和對高效調查方法的需求不斷成長，生物模擬已成為克服科學和經濟障礙的重要工具。在這種環境下，預測分析和複雜生物模型的結合對於推進臨床前和臨床試驗至關重要。隨著產業越來越傾向於數據主導策略，當今的生物模擬策略為突破性進展鋪平了道路，有可能改變患者照護並提高世界各地的行業標準。

改變生物模擬市場

在科技的快速進步和調查方法的模式轉移的推動下，生物模擬環境正在經歷巨大的變革時期。傳統的實驗室實驗正逐漸被數位和計算替代方案所取代，這些替代方案不僅提高了速度，還增加了分析深度。自動化、機器學習和高保真模擬模型的結合使研究人員能夠以前所未有的清晰度探索複雜的生物現象。這種轉變的特徵是從依賴經驗數據收集轉向預測模型，從而實現更快的假設檢驗和明智的決策。此外，模擬平台的進步提供了多種工具來滿足藥物研究不同方面的獨特要求。因此，該行業正在採用更靈活的框架，其中迭代設計和虛擬測試是業務藍圖的核心，而不僅僅是互補的活動。監管觀點的改變和數位模擬結果的日益接受進一步強調了這種轉變，使得生物模擬成為現代治療方法創新和研究中越來越不可或缺的一部分。

生物模擬分割及其意義的詳細分析

市場以多種方式細分，讓人們得以一窺生物模擬的高階層面。根據所提供的服務，市場細分為服務和軟體，服務市場進一步細分為合約服務和內部服務。另一方面，軟體類別包括各種專業工具，如分子建模和模擬軟體、PBPK建模和模擬軟體、PK/PD建模和模擬軟體、毒性預測軟體、研究設計軟體等。另一個維度是基於交付模式，區分所有權和訂閱模式，這反映了不同的投資策略和存取偏好。此外，基於應用的細分突出了藥物開發和藥物發現的雙重重點。藥物開發本身分為臨床試驗和臨床前試驗等細微差別，後者進一步細分為 ADME/Tox 和 PK/PD 考慮。相較之下，藥物發現強調目標識別和檢驗以及先導物識別和最佳化等技術。最後，基於最終用戶的細分將市場分為受託研究機構、製藥和生物技術公司、監管機構和研究機構，每個組織在推動生物模擬價值鏈方面發揮獨特的作用。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 專注於個人化醫療研究
      • 監管機構核准使用生物模擬技術促進安全藥物的開發
    • 限制因素
      • 生物模擬安裝和技術開發價格上漲
    • 機會
      • 模擬解決方案的持續進步將增強新型生物療法
      • 增加對藥物開發和測試的投資
    • 任務
      • 複雜性和缺乏產生準確結果的意識
  • 市場區隔分析
    • 我們提供的服務：生物模擬擴大使用提供模型建構、模擬、分析和視覺化平台的軟體。
    • 交付模式：由於生物模擬的前期成本較低，所有權模式越來越受到青睞。
    • 應用：擴大生物模擬在臨床試驗的應用
    • 最終用戶：製藥和生物技術公司擴大採用生物模擬
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 生物模擬市場（按類型）

  • 服務
    • 合約服務
    • 內部服務
  • 軟體
    • 分子建模與模擬軟體
    • PBPK建模與模擬軟體
    • PK/PD建模和模擬軟體
    • 毒性預測軟體
    • 測試設計軟體

第7章 生物模擬市場（依交付模式）

  • 所有權模式
  • 訂閱模式

第8章 生物模擬市場（按應用）

  • 藥物開發
    • 臨床試驗
    • 臨床前試驗
      • ADME/毒性
      • PK/PD
  • 藥物研發
    • 線索辨識與最佳化
    • 目標識別和檢驗

第9章 生物模擬市場（按最終用戶）

  • 合約研究組織
  • 製藥和生物技術公司
  • 監管機構
  • 研究機構

第 10 章：美洲生物模擬市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第 11 章亞太地區生物模擬市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 12 章歐洲、中東和非洲生物模擬市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Crystal Pharmatech Co., Ltd.
  • Cytel Inc.
  • Dassault Systemes SE
  • ICON PLC
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • Instem PLC
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life
  • VIRTUALMAN
  • Yokogawa Electric Corporation
Product Code: MRR-2D64BA93AB17

The Biosimulation Market was valued at USD 3.10 billion in 2023 and is projected to grow to USD 3.55 billion in 2024, with a CAGR of 14.60%, reaching USD 8.07 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 3.10 billion
Estimated Year [2024] USD 3.55 billion
Forecast Year [2030] USD 8.07 billion
CAGR (%) 14.60%

Biosimulation has emerged as a vital tool that is reshaping the life sciences landscape. This discipline blends advanced computational algorithms with biological data to streamline and enhance research activities, offering a more precise and cost-effective alternative to traditional experimental procedures. Today, innovative organizations are leaning into systems that can predict outcomes, simulate drug interactions, and optimize clinical trial designs. By leveraging sophisticated simulation tools, the market is witnessing accelerated development cycles, improved decision-making, and reduced risk in drug discovery and development. The proliferation of digital technologies and increased demand for efficient research methodologies have propelled biosimulation into the spotlight as a key enabler for overcoming scientific and financial hurdles. In this environment, the fusion of predictive analytics with complex biological models is proving indispensable in advancing both preclinical and clinical studies. With the industry increasingly leaning on data-driven strategies, today's biosimulation strategies pave the way for breakthroughs that hold the potential to transform patient care and elevate industry standards across the globe.

Transformative Shifts in the Biosimulation Landscape

The biosimulation landscape is undergoing profound transformations, fueled by rapid technological advancements and a paradigm shift in research methodologies. Traditional laboratory experiments are gradually making way for digital and computational alternatives that offer not only speed but also a greater depth of analysis. The integration of automation, machine learning, and high-fidelity simulation models is empowering researchers to explore complex biological phenomena with unprecedented clarity. These transformative shifts are characterized by a move from reliance on empirical data collection towards predictive modeling, enabling faster hypothesis testing and more informed decision-making. Moreover, the evolution of simulation platforms is providing versatile tools that cater to the unique requirements of various aspects of pharmaceutical research. As a result, the industry is embracing a more agile framework where iterative design and virtual testing are not just complementary activities, but central to the operational blueprint. The changes in regulatory perspectives and the growing acceptance of digitally simulated outcomes further underline this transition, making biosimulation an increasingly integral part of modern therapeutic innovation and research.

In-Depth Analysis of Biosimulation Segmentation and Its Implications

The market is segmented in multiple ways which offer a window into the sophisticated layers of biosimulation. When viewed based on the offering, the market divides into services and software, where services are further broken down into contract services and in-house services, whereas the software category encompasses a range of specialized tools including molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, toxicity prediction software, and trial design software. Another dimension is based on the delivery model, which distinguishes between ownership models and subscription models, reflecting varied investment strategies and access preferences. Moreover, application-based segmentation highlights the dual focus on drug development and drug discovery. Drug development itself spirals into nuances such as clinical trials and preclinical testing, with the latter further delineated into ADME/Tox and PK/PD considerations. In contrast, drug discovery emphasizes techniques such as lead identification and optimization alongside target identification and validation. Lastly, segmentation based on end-user categorizes the market according to contract research organizations, pharmaceutical and biotechnology companies, regulatory authorities, and research institutes, each playing their distinct role in driving the biosimulation value chain.

Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software.

Based on Delivery Model, market is studied across Ownership Models and Subscription Models.

Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation.

Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes.

Regional Dynamics Shaping the Global Biosimulation Market

Regional insights reveal a complex mosaic of opportunities and challenges that are reshaping the biosimulation arena. In the Americas, a blend of strong research institutions and robust funding mechanisms fosters an environment where biosimulation tools are rapidly adopted and refined. The region stands out with its strong regulatory frameworks and strategic partnerships that spearhead innovation. In the Europe, Middle East & Africa region, the convergence of academic research and industrial expertise creates a vibrant ecosystem. Here, well-established pharmaceutical hubs collaborate with technology providers to drive efficiency and bolster regulatory compliance, ensuring that simulation technologies align with regional standards. Meanwhile, the Asia-Pacific region is witnessing significant growth fueled by increasing investments in research and development, a surge in tech-driven startups, and expanding capabilities in digital health. This geographically diverse spread of opportunities underscores the need for tailored strategies that cater to local market dynamics, competitive pressures, and intercultural variations in research methodologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Industry Leaders Driving Biosimulation Innovation

Industry insights highlight the emergence of several key players who are instrumental in advancing the field of biosimulation. Leaders such as Advanced Chemistry Development, Inc. and Aitia are at the forefront of integrating computational modeling into everyday research routines. Companies like Allucent, Biomed Simulation, Inc., and BioSimulation Consulting Inc. bring specialized expertise that enhances the scope and precision of simulation strategies employed throughout the sector. This is complemented by the innovation drive of Cadence Design Systems, Inc., Cell Works Group, Inc., and Certara, Inc., along with Chemical Computing Group ULC and Crystal Pharmatech Co., Ltd. Additional trailblazers including Cytel Inc., Dassault Systemes SE, ICON PLC, and In Silico Biosciences, Inc. are redefining industry benchmarks. INOSIM Software GmbH, Instem PLC, Model Vitals, and Physiomics PLC, among others like Quotient Sciences Limited, Resolution Medical, and Schrodinger, Inc., further bolster the competitive landscape. The influence of companies such as Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation cannot be overstated in the ongoing drive towards more efficient, reliable, and transformative biosimulation methodologies.

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Crystal Pharmatech Co., Ltd., Cytel Inc., Dassault Systemes SE, ICON PLC, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation. Strategic Recommendations for Biosimulation Industry Leaders

For industry leaders, the evolving landscape presents multiple avenues for strategic advancement. It is imperative to invest in next-generation simulation platforms that blend advanced computational power with intuitive user interfaces, thereby enhancing both predictive accuracy and operational efficiency. Fostering partnerships with technology providers can facilitate access to innovative tools while also offering new collaborative research opportunities. Leaders should prioritize dynamic talent development programs that not only cultivate expertise in simulation technologies but also encourage cross-disciplinary synergy between data science, biology, and regulatory affairs. Embracing flexible engagement models such as subscription-based solutions may reduce upfront costs and stimulate broader adoption of emerging technologies. In addition, benchmarking against industry pioneers and integrating real-world data analytics into simulation frameworks can significantly improve overall performance. These actionable approaches offer a roadmap for capitalizing on the transformative potential of biosimulation, ensuring that organizations remain agile, competitive, and well-equipped to address rapidly evolving market requirements.

Conclusion: The Future of Biosimulation in a Rapidly Evolving Landscape

In summary, the biosimulation market is positioned at a critical juncture where technological innovation and strategic foresight converge to redefine research paradigms. The shift from conventional experimental models to data-driven simulation techniques underscores the importance of adaptability and proactive investment in advanced methodologies. A detailed segmentation analysis reveals the multifaceted nature of the market, spanning various offerings, delivery models, applications, and end-users. This complexity is further complemented by distinct regional dynamics and the presence of pioneering companies whose innovative endeavors are setting new industry benchmarks. The insights gained from examining these factors converge to offer a comprehensive understanding of the current state and future trajectory of biosimulation. Ultimately, the key to sustained success in this rapidly evolving field lies in the ability to harness technological advancements, nurture collaborative ecosystems, and maintain a steadfast commitment to continuous improvement and operational excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing emphasis on research of personalized medicine
      • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
      • 5.1.3.2. Rising investments for drug developments and drug testings
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
    • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation owing to its lower initial costs
    • 5.2.3. Application: Increasing application of biosimulation for clinical trials
    • 5.2.4. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimulation Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
    • 6.2.1. Contract Services
    • 6.2.2. In-House Services
  • 6.3. Software
    • 6.3.1. Molecular Modeling & Simulation Software
    • 6.3.2. PBPK Modeling & Simulation Software
    • 6.3.3. PK/PD Modeling & Simulation Software
    • 6.3.4. Toxicity Prediction Software
    • 6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model

  • 7.1. Introduction
  • 7.2. Ownership Models
  • 7.3. Subscription Models

8. Biosimulation Market, by Application

  • 8.1. Introduction
  • 8.2. Drug Development
    • 8.2.1. Clinical Trials
    • 8.2.2. Preclinical Testing
      • 8.2.2.1. ADME/Tox
      • 8.2.2.2. PK/PD
  • 8.3. Drug Discovery
    • 8.3.1. Lead Identification & Optimization
    • 8.3.2. Target Identification & Validation

9. Biosimulation Market, by End-User

  • 9.1. Introduction
  • 9.2. Contract Research Organizations
  • 9.3. Pharmaceutical & Biotechnology Companies
  • 9.4. Regulatory Authorities
  • 9.5. Research Institutes

10. Americas Biosimulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biosimulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. ProductLife Group enhances drug development capabilities with IntiQuan acquisition for innovative biosimulation solutions
    • 13.3.2. Cytel's new East Horizon platform enhances adaptive trial design with cloud integration
    • 13.3.3. Orion and Aitia leverage AI-driven digital twins to revolutionize drug discovery in oncology sector
    • 13.3.4. Biosimulation and tumor microenvironment modeling enhance precision of immunotherapy predictions for NSCLC patients
    • 13.3.5. Quantum breakthroughs in biosimulation revolutionize drug discovery with cutting-edge precision modeling
    • 13.3.6. Certara to acquire Chemaxon to enhance drug discovery and biosimulation capabilities
    • 13.3.7. Simulations Plus expands drug development capabilities with USD 100 million acquisition of Pro-Pro-ficiency Holdings, Inc.
    • 13.3.8. Cellworks unveils new CLIA-certified lab in Tennessee enhancing personalized NSCLC treatment with biosimulation technology and expert leadership
    • 13.3.9. ZETA Group acquires majority stake in INOSIM to revolutionize simulation and engineering in biopharma industry
    • 13.3.10. Innovative cloud-based biosimulation partnership between Exploristics and Exonate revolutionizes clinical trial design for retinal disease therapies
    • 13.3.11. Certara launches Pirana Modeling Workbench 23.10.1 with advanced machine learning and new VPC GUI
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Simulations Plus, Inc.
    • 13.4.2. Cadence Design Systems, Inc.
    • 13.4.3. Dassault Systemes SE
    • 13.4.4. Certara, Inc.
    • 13.4.5. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. Advanced Chemistry Development, Inc.
  • 2. Aitia
  • 3. Allucent
  • 4. Biomed Simulation, Inc.
  • 5. BioSimulation Consulting Inc.
  • 6. Cadence Design Systems, Inc.
  • 7. Cell Works Group, Inc.
  • 8. Certara, Inc.
  • 9. Chemical Computing Group ULC
  • 10. Crystal Pharmatech Co., Ltd.
  • 11. Cytel Inc.
  • 12. Dassault Systemes SE
  • 13. ICON PLC
  • 14. In Silico Biosciences, Inc.
  • 15. INOSIM Software GmbH
  • 16. Instem PLC
  • 17. Model Vitals
  • 18. Physiomics PLC
  • 19. Quotient Sciences Limited
  • 20. Resolution Medical
  • 21. Schrodinger, Inc.
  • 22. Simulations Plus, Inc.
  • 23. Thermo Fisher Scientific Inc.
  • 24. VeriSIM Life
  • 25. VIRTUALMAN
  • 26. Yokogawa Electric Corporation

LIST OF FIGURES

  • FIGURE 1. BIOSIMULATION MARKET MULTI-CURRENCY
  • FIGURE 2. BIOSIMULATION MARKET MULTI-LANGUAGE
  • FIGURE 3. BIOSIMULATION MARKET RESEARCH PROCESS
  • FIGURE 4. BIOSIMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMULATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 340. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 349. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 350. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 351. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 358. SPAIN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 359. SPAIN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 360. SPAIN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 365. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 366. SPAIN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. SWEDEN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 368. SWEDEN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 369. SWEDEN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 370. SWEDEN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 371. SWEDEN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (U